StockData
vTv Therapeutics Inc. logo

vTv Therapeutics Inc. (VTVT) company profile

VTVTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/3062% below fair value
$16.23−1.06 (-6.13%)

Close on Nov 18, 2026Market cap $64.17MP/E –Yield –

About vTv Therapeutics

Pharmaceutical Preparations, SIC 2834

The company is a clinical-stage biopharmaceutical firm that discovers and develops oral therapies for metabolic and inflammatory conditions. Its primary drug candidate is cadisegliatin, an oral liver-selective glucokinase activator in late-stage development as an add-on treatment to insulin for individuals with type 1 and type 2 diabetes. Its broader research pipeline features oral small molecules including a GLP-1 receptor agonist for diabetes management, a preclinical RAGE antagonist, Nrf2 pathway activators for inflammation, and a globally licensed PDE4 inhibitor. The company targets patients suffering from chronic metabolic and autoimmune disorders, while collaborating with commercial partners and research institutions.

The company conducts clinical development programs and maintains commercial partnerships across the United States, the Middle East, Africa, Central Asia, and the Pacific Rim. Its clinical operations encompass multiple studies, including a Phase 3 study evaluating 150 patients and a 300-patient regional study. The provided text does not state the location of the company's corporate headquarters.

Summary of the business section of vTv Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
vTv Therapeutics Inc.
Founded
2015
Headquarters
High Point, NC
Address
3980 Premier Dr, Suite 310 27265
Phone
(336) 841-0300
Employees
26, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Detroit, Michigan

Stock & identifiers

Ticker
VTVT
Exchange
Nasdaq
IPO date
Jul 31, 2015
Shares outstanding
4M, Aug 6, 2026
Public float
$22.36M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-40 reverse, Nov 21, 2023
SEC CIK
1641489
CUSIP
918385204
ISIN
US9183852048
FIGI
BBG009DT9XJ0
Share class FIGI
BBG009DT9XK8
LEI
549300WQE5EI9R35SE66
EIN
47-3916571

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Paul J. SekhriPres, CEO and Exec Chairperson, Director392,212
Michael Stephen TungEVP & CFO–
Barry K. BrownChief Accounting Officer4
Felix BakerDirector–
Brothers Life Sciences LP BakerDirector–
Bros. Advisors (GP) LLC BakerDirector–
667, L.P.Director89,254
Daniel K. SpiegelmanDirector–
Fahed Al-MarzooqiDirector–
Srinivas AkkarajuDirector312,784
Bros. Advisors Lp BakerDirector142,135
Julian BakerDirector12,368
Anne M. PhillipsDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$6.64M$5.73M$1.29M$143–
FY2024$3.86M$1.98M$1.52M$51–
FY2023$1.33M$697.40K$670.25K$42–
FY2022$373.66K$335.21K$393.53K$65–
FY2022
Nelson
$680.74K$647.87K$393.53K$65–
FY2022
Nelson And Prasad
$1.68M-$63.28K$393.53K$65–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payOtherTotalvs. prior year
Paul Sekhri
President and Chief Executive Officer
$673.00K$5.60M$343.23K$20.31K$6.64M+72%
Michael Tung
Executive Vice President and Chief Financial Officer
$279.55K$2.02M$135.05K$8.66K$2.44M–
Steven Tuch
Former Executive Vice President and Chief Financial Officer
$107.39K––$34.91K$142.30K-91%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jul 31, 2015
Offer price
$15.00
Securities offered
7,812,500
Gross proceeds
$117.19M
Exchange
Nasdaq
First trading day
Jul 30, 2015
First-day close
$10.89-27.4%
Lock-up ends (est.)
Jan 26, 2016

“The initial public offering price is $15.00 per ordinary share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025 we had twenty-six employees and none of our employees are represented by a labor union, and we consider our employee relations to be good.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?